Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies

被引:24
作者
Acher, Alexandra W. [2 ]
Paro, Alessandro [2 ]
Elfadaly, Ahmed [2 ]
Tsilimigras, Diamantis [2 ]
Pawlik, Timothy M. [1 ,2 ]
机构
[1] Ohio State Univ Wexner Med Ctr, James Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA
关键词
intrahepatic; cholangiocarcinoma; biomarkers; outcomes; trials; METASTATIC CHOLANGIOCARCINOMA; TYROSINE KINASE; RISK-FACTORS; OPEN-LABEL; MUTATIONS; EPIDEMIOLOGY; MULTICENTER; EXPRESSION; FREQUENCY; GENE;
D O I
10.3390/cancers13205169
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although rare, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy and the incidence of ICC has increased 14% per year in recent decades. Treatment of ICC remains difficult as most people present with advanced disease not amenable to curative-intent surgical resection. Even among patients with operable disease, margin-negative surgical resection can be difficult to achieve and the incidence of recurrence remains high. As such, there has been considerable interest in systemic chemotherapy and targeted therapy for ICC. Over the last decade, the understanding of the molecular and genetic foundations of ICC has reshaped treatment approaches and strategies. Next-generation sequencing has revealed that most ICC tumors have at least one targetable mutation. These advancements have led to multiple clinical trials to examine the safety and efficacy of novel therapeutics that target tumor-specific molecular and genetic aberrations. While these advancements have demonstrated survival benefit in early phase clinical trials, continued investigation in randomized larger-scale trials is needed to further define the potential clinical impact of such therapy.
引用
收藏
页数:15
相关论文
共 65 条
[1]   Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].
Abou-Alfa, Ghassan K. ;
Macarulla, Teresa ;
Javle, Milind M. ;
Kelley, Robin K. ;
Lubner, Sam J. ;
Adeva, Jorge ;
Cleary, James M. ;
Catenacci, Daniel V. ;
Borad, Mitesh J. ;
Bridgewater, John ;
Harris, William P. ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Whisenant, Jonathan ;
Lowery, Maeve A. ;
Goyal, Lipika ;
Shroff, Rachna T. ;
El-Khoueiry, Anthony B. ;
Fan, Bin ;
Wu, Bin ;
Chamberlain, Christina X. ;
Jiang, Liewen ;
Gliser, Camelia ;
Pandya, Shuchi S. ;
Valle, Juan W. ;
Zhu, Andrew X. .
LANCET ONCOLOGY, 2020, 21 (06) :796-807
[2]   Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].
Abou-Alfa, Ghassan K. ;
Sahai, Vaibhav ;
Hollebecque, Antoine ;
Vaccaro, Gina ;
Melisi, Davide ;
Al-Rajabi, Raed ;
Paulson, Andrew S. ;
Borad, Mitesh J. ;
Gallinson, David ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Dotan, Efrat ;
Catenacci, Daniel, V ;
Van Cutsem, Eric ;
Ji, Tao ;
Lihou, Christine F. ;
Zhen, Huiling ;
Feliz, Luis ;
Vogel, Arndt .
LANCET ONCOLOGY, 2020, 21 (05) :671-684
[3]  
Ahrendt S A, 2000, J Hepatobiliary Pancreat Surg, V7, P426, DOI 10.1007/s005340070039
[4]   Different roles of S100P Overexpression in Intrahepatic Cholangiocarcinoma: Carcinogenesis of Perihilar Type and Aggressive Behavior of Peripheral Type [J].
Aishima, Shinichi ;
Fujita, Nobuhiro ;
Mano, Yohei ;
Kubo, Yuichiro ;
Tanaka, Yuki ;
Taketomi, Akinobu ;
Shirabe, Ken ;
Maehara, Yoshihiko ;
Oda, Yoshinao .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2011, 35 (04) :590-598
[5]   Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors [J].
Andersen, Jesper B. ;
Spee, Bart ;
Blechacz, Boris R. ;
Avital, Itzhak ;
Komuta, Mina ;
Barbour, Andrew ;
Conner, Elizabeth A. ;
Gillen, Matthew C. ;
Roskams, Tania ;
Roberts, Lewis R. ;
Factor, Valentina M. ;
Thorgeirsson, Snorri S. .
GASTROENTEROLOGY, 2012, 142 (04) :1021-U552
[6]   Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection [J].
Bagante, Fabio ;
Spolverato, Gaya ;
Merath, Katiuscha ;
Weiss, Matthew ;
Alexandrescu, Sorin ;
Marques, Hugo P. ;
Aldrighetti, Luca ;
Maithel, Shishir K. ;
Pulitano, Carlo ;
Bauer, Todd W. ;
Shen, Feng ;
Poultsides, George A. ;
Soubrane, Olivier ;
Martel, Guillaume ;
Koerkamp, B. Groot ;
Guglielmi, Alfredo ;
Endo, Itaru ;
Pawlik, Timothy M. .
SURGERY, 2019, 166 (06) :983-990
[7]   Clinical diagnosis and staging of cholangiocarcinoma [J].
Blechacz, Boris ;
Komuta, Mina ;
Roskams, Tania ;
Gores, Gregory J. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2011, 8 (09) :512-522
[8]   Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors [J].
Cardinale, Vincenzo ;
Semeraro, Rossella ;
Torrice, Alessia ;
Gatto, Manuela ;
Napoli, Cristina ;
Bragazzi, Maria Consiglia ;
Gentile, Raffaele ;
Alvaro, Domenico .
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 2 (11) :407-416
[9]   Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm [J].
Chakrabarti, Sakti ;
Kamgar, Mandana ;
Mahipal, Amit .
CANCERS, 2020, 12 (08) :1-21
[10]   The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival [J].
Choi, Sae-Byeol ;
Kim, Kyung-Sik ;
Choi, Jin-Young ;
Park, Seung-Woo ;
Choi, Jin-Sub ;
Lee, Woo-Jung ;
Chung, Jae-Bock .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (11) :3048-3056